At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Trading 03-18 10:43:11 EDT
16.48
-0.29
-1.73%
High16.76Low16.43Vol112.56K
Open16.75D1 Closing16.77Amplitude1.97%
Mkt Cap1.18BTradable Cap666.05MTotal Shares71.37M
T/O1.87MT/O Rate0.28%Tradable Shares40.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
TIPRANKS  ·  03-13
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
MoonLake Immunotherap Is Maintained at Buy by Clear Street
Dow Jones  ·  03-11
MoonLake Immunotherap Is Maintained at Buy by Clear Street
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)
TIPRANKS  ·  03-11
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)
MoonLake price target raised to $70 from $45 at Clear Street
TIPRANKS  ·  03-11
MoonLake price target raised to $70 from $45 at Clear Street
MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed?
Simply Wall St.  ·  03-03
MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed?
MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-02
MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.
RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk
MT Newswires Live  ·  03-02
RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk
RBC Capital Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  03-02
RBC Capital Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
TIPRANKS  ·  03-02
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $40 From $32
THOMSON REUTERS  ·  03-02
MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $40 From $32
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Genfit (OtherGNFTF)
TIPRANKS  ·  03-02
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Genfit (OtherGNFTF)
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
TIPRANKS  ·  02-26
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
MoonLake Immunotherap Price Target Maintained With a $25.00/Share by Needham
Dow Jones  ·  02-26
MoonLake Immunotherap Price Target Maintained With a $25.00/Share by Needham
MoonLake posts FY 2025 interest expense of USD 7.2 million
Reuters  ·  02-25
MoonLake posts FY 2025 interest expense of USD 7.2 million
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
TIPRANKS  ·  02-24
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
MoonLake Immunotherapeutics : Leerink Partners Raises Target Price to $24 From $20
THOMSON REUTERS  ·  02-24
MoonLake Immunotherapeutics : Leerink Partners Raises Target Price to $24 From $20
MoonLake Immunotherap Is Maintained at Buy by Needham
Dow Jones  ·  02-24
MoonLake Immunotherap Is Maintained at Buy by Needham
Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept
MT Newswires Live  ·  02-24
Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and PROCEPT BioRobotics (PRCT)
TIPRANKS  ·  02-24
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and PROCEPT BioRobotics (PRCT)
BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase
Reuters  ·  02-23
BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--